Evidence map›Paper›PMID 31079357›Full record

ArticleDiabetes therapy : research, treatment and education of diabetes and related disorders2019

Efficacy and Safety of Switching to Teneligliptin in Patients with Type 2 Diabetes Inadequately Controlled with Dipeptidyl Peptidase-4 Inhibitors: A 12-Week Interim Report.

Hae Jin Kim, Young Sik Kim, Chang Beom Lee, Moon-Gi Choi, Hyuk-Jae Chang, Soo Kyoung Kim, Jae Myung Yu, Tae Ho Kim, Ji Hyun Lee, Kyu Jeung Ahn and 2 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes therapy : research, treatment and education of diabetes and related disorders, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03793023 (Observational Study to Evaluate the Efficacy and Safety of Teneligliptin When Switched From Other DPP-4 Inhibitors in Type 2 DM With Inadequate Glycemic Control), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03793023 completednot on this map

Observational Study to Evaluate the Efficacy and Safety of Teneligliptin When Switched From Other DPP-4 Inhibitors in Type 2 DM With Inadequate Glycemic Control

TypeobservationalSponsorHandok Inc.Ran2016 to 2019Enrolled2,983ConditionsType 2 Diabetes MellitusArmsTeneligliptin 20mg
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Observational
  2. Observational
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Hae Jin KimDepartment of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, Korea.
Young Sik KimDepartment of Family Medicine, University of Ulsan College of Medicine, Seoul, Korea.
Chang Beom LeeDepartment of Internal Medicne, Hanyang University College of Medicine, Guri, Korea.
Moon-Gi ChoiDepartment of Internal Medicine, College of Medicine, Hallym University, Chuncheon, Korea.
Hyuk-Jae ChangDepartment of Cardiology, Yonsei University College of Medicine, Seoul, Korea.
Soo Kyoung KimDepartment of Internal Medicine, Gyeongsang National University School of Medicine, Jinju, Korea.
Jae Myung YuDepartment of Internal Medicine, Hallym University College of Medicine, Seoul, Korea.
Tae Ho KimDepartment of Internal Medicine, Seoul Medical center, Seoul, Korea.
Ji Hyun LeeDepartment of Internal Medicine, Catholic University of Daegu, Korea, Daegu, Korea.
Kyu Jeung AhnDepartment of Endocrinology and Metabolism, Kyung Hee University School of Medicine, Seoul, Korea.
Kyoungmin KimMedical Affairs, Handok Inc, Seoul, Korea.
Kwan Woo LeeDepartment of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, Korea. lkw65@ajou.ac.kr.

Funding

HSRD VA PPO 15-410
6 · The paper itself

Abstract

introductionTeneligliptin, an antidiabetic agent classified as a class III dipeptidyl peptidase-4 (DPP-4) inhibitor, has a unique structural feature that provides strong binding to DPP-4 enzymes. We investigated the efficacy and safety of switching patients with type 2 diabetes mellitus (T2DM) who had inadequate glycemic control on a stable dose of other DPP-4 inhibitors to teneligliptin.

methodsPatients with T2DM whose glycosylated hemoglobin (HbA1c) levels were ≥ 7% despite taking DPP-4 inhibitors other than teneligliptin, with or without other hypoglycemic agents, for at least 3 months were enrolled. The DPP-4 inhibitors taken before participating in the study were switched to 20 mg qd teneligliptin, and this was to be maintained for 52 weeks. The primary end point was the change in HbA1c levels after 12 weeks. Metabolic parameters including fasting plasma glucose (FPG) and blood lipids were assessed also. To assess safety, adverse and hypoglycemic events were monitored. The data from baseline to week 12 were used for analysis in this interim report.

resultsThe mean change in HbA1c levels from baseline to week 12 was - 0.44%. At week 12, the percentage of patients achieving HbA1c < 7.0% was 31.6% and that of achieving HbA1c < 6.5% was 11.4%, respectively. In 41.2% of patients, the HbA1c levels decreased by at least 0.5% at 12 weeks. The mean change in FPG levels from baseline to week 12 was - 11.5 mg/dl. No severe hypoglycemia was reported.

conclusionAfter switching to teneligliptin, HbA1c levels decreased significantly in patients with T2DM inadequately controlled with other DPP-4 inhibitors.

trial registrationClinicalTrials.gov, NCT03793023.

fundingHandok Inc.

Indexed as

Diabetes mellitus, Type 2Dipeptidyl-peptidase IV inhibitorsTeneligliptin

Identifiers

PMID31079357
PMCPMC6612358

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.